Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
luvqs / Pixabay

Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

  The FDA has recently approved of Viking Therapeutics' Investigational New Drug (IND) application, which allows patients to enroll in their clinical trials. In order to qualify for these trials,…

Continue Reading Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

Hanson Wade’s 2nd Annual NASH Summit

  • Post author:
  • Post category:

Presenting the 2nd Annual NASH Summit 2018 This summit will specialize keeping drug companies and research organizations up to date on new information relevant to the development of new treatments…

Continue Reading Hanson Wade’s 2nd Annual NASH Summit